The aime of the study is to assess the efficacy, safety and cost-effectiveness of this vaccine in prevention of lower respiratory tract infections (LRTIs) in Chinese elderly.
600 subjects of 60 years old were divided into experimental and control groups( 300 each group). Data on name, sex, age, smoking and exercise habits, monthly per capita income, living conditions, influenza vaccine status, immunoenhancers use and diseases –particularly LRTIs –3 months prior to the study were collected for baseline comparison. During a 1-year follow-up period, both groups were observed for incidence and severity of LRTIs, hospitalization rates, length of hospital stay, antibiotic use and direct medical costs.
Overall, the vaccine reduced LRTIs, antibiotic use and hospitalization by 69.7%, 72.6% and 65.9%, respectively. Stratified analysis showed vaccine reduced the incidence and severity of LRTIs as well as rates of antibiotic use and hospitalization in subjects with COPD or CHD. In subjects who had diabetes mellitus, hypertension or were inoculated with the influenza vaccine, the vaccine was a protective factor in LRTIs and rate of antibiotic use, but reductions in hospitalization rates were not significant. The vaccine did not reduce the incidence and severity of LRTIs or the rates of antibiotic use and hospitalization in subjects classified as healthy. Side effects were noted in 91 subjects, including 80 with local reactions at the injection site, 9 with systemic reactions, and two with both local and systemic reactions. All adverse reactions were mild and resolved within 1 to 3 days by local stupe or rest.The benefit-cost ratio was 2.06, with a net benefit of ¥66,471.65.
23-valent pneumococcal polysaccharide vaccination among the elderly community is effective in reducing the incidence and severity of LRTIs. It also decreases antibiotic use the frequency and duration of hospitalization.
The protective efficacy of this vaccine is particularly significant in patients with COPD and CHD and it is cost-effective and safe.
Bi Dong, None.